Laboratory for Investigative Dermatology, Rockefeller University, New York, NY 10065, USA.
J Allergy Clin Immunol. 2011 Jun;127(6):1420-32. doi: 10.1016/j.jaci.2011.01.054. Epub 2011 Mar 21.
Atopic dermatitis (AD) and psoriasis are among the most common inflammatory skin diseases. In the first part of this 2-part review, we discussed the similarities and differences between AD and psoriasis with respect to clinical features and pathology. The diseases are characterized by infiltration of skin lesions by large numbers of inflammatory cells; the second part of this review focuses on immune cell subsets that distinguish each disease and the therapeutic strategies that might be used or developed based on this information. We discuss the interactions among different populations of immune cells that ultimately create the complex inflammatory phenotype of AD and compare these with psoriasis. Therapeutic strategies have been developed for psoriasis based on the cytokine network that promotes inflammation in this disease. Antibodies against IL-12 and IL-23p40 antibody and antagonists of TNF are used to treat patients with psoriasis, and studies are underway to test specific antagonists of IL-23, IL-17, IL-17 receptor, IL-20, and IL-22. We discuss how these therapeutic approaches might be applied to AD.
特应性皮炎（AD）和银屑病是最常见的炎症性皮肤病之一。在这篇 2 部分综述的第一部分中，我们讨论了 AD 和银屑病在临床特征和病理学方面的异同。这两种疾病的特征是大量炎症细胞浸润皮肤病变；这篇综述的第二部分重点介绍了区分每种疾病的免疫细胞亚群，以及可能基于这些信息开发或使用的治疗策略。我们讨论了不同免疫细胞群之间的相互作用，这些相互作用最终导致了 AD 的复杂炎症表型，并将其与银屑病进行了比较。基于促进这种疾病炎症的细胞因子网络，已经为银屑病开发了治疗策略。针对 IL-12 和 IL-23p40 抗体以及 TNF 拮抗剂的抗体被用于治疗银屑病患者，并且正在进行研究以测试针对 IL-23、IL-17、IL-17 受体、IL-20 和 IL-22 的特异性拮抗剂。我们讨论了如何将这些治疗方法应用于 AD。
